Name: 글로벌 시장 동향
SKU: PH1486
Availability: InStock

보고서 요약(국문)

시장 개요
T세포 림프종 시장은 2022년 14억 8,520만 달러에 달했으며, 2030년까지 27억 8,780만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. T세포 림프종 시장은 예측 기간(2023~2030년) 동안 연평균 8.4%의 성장률을 기록할 것으로 전망됩니다.
T세포 림프종은 말초 T세포 림프종과 T세포 림프모세포 림프종으로 분류됩니다. T세포 림프종은 화학요법, 방사선요법, 면역요법, 항바이러스제, 줄기세포 이식 및 기타 치료법으로 치료할 수 있습니다.
T세포 림프종 시장의 성장은 방사선으로 인한 림프종 발병률 증가, T세포 림프종 특이적 치료법의 개발, 자가면역 질환으로 인한 림프종 발병 위험 증가 등에 기인합니다.

시장 동향
전 세계 암 발병률 증가
전 세계 암 발병률 증가는 T세포 림프종 시장 기회에 영향을 미치는 주요 요인 중 하나입니다. 의료 인프라 투자 증가와 고령 인구 증가 또한 T세포 림프종 시장 확대를 이끄는 요인입니다.
세계보건기구(WHO)에 따르면 암은 전 세계 사망 원인 1위이며, 2020년에는 약 1천만 명이 암으로 사망하여 전체 사망자의 약 6분의 1을 차지했습니다. 매년 약 40만 명의 어린이가 암에 걸립니다. 가장 흔한 암의 종류는 국가별로 다릅니다.
높은 치료 비용 및 장기간 치료
T세포 림프종 치료는 독특한 작용 기전과 세포 채취 및 제조 과정으로 인해 매우 고비용입니다. 치료 비용은 환자의 질병 정도와 필요한 치료 수준에 따라 환자마다 다릅니다.

COVID-19 영향 분석
코로나19 팬데믹은 암 치료 서비스의 중단과 암 치료 임상 시험의 중단으로 인해 예측 기간 동안 전 세계 T세포 림프종 시장 추세에 부정적인 영향을 미쳤습니다.
코로나19 유행으로 인해 피부 림프종 환자들은 병원 접근의 어려움이나 의료 자원 부족으로 인해 중요한 진단 검사 및 치료를 받지 못할 위험이 커졌습니다.
세그먼트 분석
화학 요법 부문은 예측 기간 동안 약 40.8%의 시장 점유율로 시장을 주도할 것입니다.
화학 요법은 암세포의 증식을 억제하고 늦추기 때문에 T세포 림프종에 흔히 사용되는 치료법입니다. 수술 및 방사선 치료와 더불어 화학 요법은 전신에 영향을 미칠 수 있습니다. 이러한 치료법은 신체의 특정 부위에 있는 암세포를 파괴하거나 제거할 수 있습니다.

또한, CHOP(사이클로포스파미드, 독소루비신, 빈크리스틴, 프레드니손), CHOEP(에토포사이드, 빈크리스틴, 독소루비신, 사이클로포스파미드, 프레드니손) 또는 기타 다중 약물 요법과 같은 복합 항암 화학 요법이 치료에 자주 사용됩니다.
지역 분석
북미는 예측 기간 동안 전체 시장의 42.4%를 차지하며 시장을 주도할 것으로 예상됩니다.
전 세계 T세포 림프종 시장은 북미 지역의 높은 T세포 림프종 발병률, 강력한 경쟁업체 존재, 그리고 활발한 연구 활동으로 인해 북미 지역에서 큰 규모를 자랑합니다. 또한, T세포 림프종은 비호지킨 림프종의 아형이며, 비호지킨 림프종 발병률 증가는 새로운 치료 옵션에 대한 수요를 증가시켜 시장 성장을 촉진할 것으로 예상됩니다.

경쟁 환경
주요 글로벌 기업으로는 Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, Spectrum Pharmaceuticals 등이 있습니다.

• 보고서 구매 이유

• 유형, 최종 사용자 및 지역별 글로벌 T세포 림프종 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위해

• 모든 세그먼트를 포함한 글로벌 T세포 림프종 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 제공

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공

• 주요 기업의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑 제공

글로벌 T세포 림프종 시장 보고서는 약 92개의 표, 108개의 그림, 195페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).
T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.
The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.
Market Dynamics
Increase in Prevalence of Cancer Worldwide
The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.
According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.
High Cost and Long Duration of Treatment
Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.
COVID-19 Impact Analysis
The Covid-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.
Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.
Segment Analysis
The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share
Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.
Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.
Geographical Analysis
North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market
The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.
Competitive Landscape
The major global players include Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.
• Why Purchase the Report?
• To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the prevalence of cancer worldwide
4.1.2. Restraints
4.1.2.1. High cost and long duration of treatment
4.1.3. Opportunity
4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Peripheral T Cell Lymphoma
7.2. Cutaneous T Cell Lymphoma
7.3. Anaplastic Large Cell Lymphoma
7.4. Others
8. By Treatment
8.1. Radiotherapy
8.2. Chemotherapy
8.3. Targeted Therapy
8.4. Surgery
8.5. Stem Cell Transplantation
8.6. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1.1. The U.S.
9.2.5.1.2. Canada
9.2.5.1.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1.1. Germany
9.3.5.1.2. The UK
9.3.5.1.3. France
9.3.5.1.4. Italy
9.3.5.1.5. Spain
9.3.5.1.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1.1. Brazil
9.4.5.1.2. Argentina
9.4.5.1.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1.1. China
9.5.5.1.2. India
9.5.5.1.3. Japan
9.5.5.1.4. Australia
9.5.5.1.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Johnson & Johnson
11.2. Novartis AG
11.3. Bristol Myers Squibb Company
11.4. Merck & Co Inc
11.5. F.Hoffmann La Roche Ltd
11.6. Acrotech Biopharma
11.7. GlaxoSmithKline Plc
11.8. Spectrum Pharmaceuticals
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, Spectrum Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global T Cell Lymphoma Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global T Cell Lymphoma Market Value, By Treatment 2023, 2027 & 2031 (US$ Million)

Table 3 Global T Cell Lymphoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global T Cell Lymphoma Market Value, By Therapy Type, 2023, 2027 & 2031 (US$ Million)

Table 5 Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 6 Global T Cell Lymphoma Market Value, By Treatment 2023, 2027 & 2031 (US$ Million)

Table 7 Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 8 Global T Cell Lymphoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global T Cell Lymphoma Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 11 North America Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 12 North America Global T Cell Lymphoma Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 14 South America Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 15 South America Global T Cell Lymphoma Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 17 Europe Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 18 Europe Global T Cell Lymphoma Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 21 Asia-Pacific Global T Cell Lymphoma Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East & Africa Global T Cell Lymphoma Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 23 Middle East & Africa Global T Cell Lymphoma Market Value, By Treatment 2022-2031 (US$ Million)

Table 24 Johnson & Johnson: Overview

Table 25 Johnson & Johnson: Product Portfolio

Table 26 Johnson & Johnson: Key Developments

Table 27 Novartis AG: Overview

Table 28 Novartis AG: Product Portfolio

Table 29 Novartis AG: Key Developments

Table 30 Bristol Myers Squibb Company: Overview

Table 31 Bristol Myers Squibb Company: Product Portfolio

Table 32 Bristol Myers Squibb Company: Key Developments

Table 33 Merck & Co Inc: Overview

Table 34 Merck & Co Inc: Product Portfolio

Table 35 Merck & Co Inc: Key Developments

Table 36 F.Hoffmann La Roche Ltd: Overview

Table 37 .F.Hoffmann La Roche Ltd: Product Portfolio

Table 38 F.Hoffmann La Roche Ltd: Key Developments

Table 39 Acrotech Biopharma: Overview

Table 40 Acrotech Biopharma: Product Portfolio

Table 41 Acrotech Biopharma: Key Developments

Table 42 GlaxoSmithKline Plc: Overview

Table 43 GlaxoSmithKline Plc: Product Portfolio

Table 44 GlaxoSmithKline Plc: Key Developments

Table 45 Spectrum Pharmaceuticals: Overview

Table 46 Spectrum Pharmaceuticals: Product Portfolio

Table 47 Spectrum Pharmaceuticals: Key Developments

Table 48 Seagen Inc: Overview

Table 49 Seagen Inc: Product Portfolio

Table 50 Seagen Inc: Key Developments

Table 51 Genmab A/S: Overview

Table 52 Genmab A/S: Product Portfolio

Table 53 Genmab A/S: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 2 Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 3 Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 4 Global T Cell Lymphoma Market Share, By Region, 2022 & 2031 (%)

Figure 5 Global T Cell Lymphoma Market Y-o-Y Growth, By Therapy Type, 2022-2031 (%)

Figure 6 Peripheral T Cell Lymphoma Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 7 Cutaneous T Cell Lymphoma Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 8 Anaplastic Large Cell Lymphoma Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 9 Others Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 10 Global T Cell Lymphoma Market Y-o-Y Growth, By Treatment, 2022-2031 (%)

Figure 11 Radiotherapy Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 12 Chemotherapy Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 13 Targeted Therapy Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 14 Surgery Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 15 Stem cell Transplantation Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 16 Others Treatment in Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 17 Global T Cell Lymphoma Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 18 North America Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 19 Asia-Pacific Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 20 Europe Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 21 South America Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 22 Middle East and Africa Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 23 North America Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 24 North America Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 25 North America Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 26 North America Global T Cell Lymphoma Market Share, By Country, 2022 & 2031 (%)

Figure 27 South America Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 28 South America Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 29 South America Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 30 South America Global T Cell Lymphoma Market Share, By Country, 2022 & 2031 (%)

Figure 31 Europe Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 32 Europe Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 33 Europe Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 34 Europe Global T Cell Lymphoma Market Share, By Country, 2022 & 2031 (%)

Figure 35 Asia-Pacific Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 36 Asia-Pacific Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 37 Asia-Pacific Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 38 Asia-Pacific Global T Cell Lymphoma Market Share, By Country, 2022 & 2031 (%)

Figure 39 Middle East & Africa Global T Cell Lymphoma Market Value, 2022-2031 (US$ Million)

Figure 40 Middle East & Africa Global T Cell Lymphoma Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 41 Middle East & Africa Global T Cell Lymphoma Market Share, By Treatment, 2022 & 2031 (%)

Figure 42 Johnson & Johnson: Financials

Figure 43 Novartis AG: Financials

Figure 44 Bristol Myers Squibb Company: Financials

Figure 45 Merck & Co Inc: Financials

Figure 46 F.Hoffmann La Roche Ltd: Financials

Figure 47 Acrotech Biopharma: Financials

Figure 48 GlaxoSmithKline Plc: Financials

Figure 49 Spectrum Pharmaceuticals: Financials

Figure 50 Seagen Inc: Financials

Figure 51 Genmab A/S: Financials

글로벌 T세포 림프종 시장 – 2023-2030

Global T-Cell Lymphoma Market - 2023-2030